• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Mannkind Corp.

The biggest diabetes tech stories out of ADA 2025

June 24, 2025 By Sean Whooley

The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]

Filed Under: Artificial Intelligence (AI), Business/Financial News, Clinical Trials, Diabetes, Drug Pumps, Drug-Device Combinations, Featured, Health Technology, In-Depth Coverage, Machine Learning (ML), Patient Monitoring, Software / IT, Special Content Tagged With: Abbott, ADA 2025, Beta Bionics, biolinq, Dexcom, Eli Lilly & Co., GlucoTrack, Insulet, LifePlus, Mannkind Corp., Medtronic, MiniMed, modularmedical, PharmaSens, Senseonics, SiBionics, Tandem Diabetes Care, Vaxess Technologies

The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions

June 25, 2024 By Sean Whooley

The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug Pumps, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Health Technology, Implants, Patient Monitoring, Pharmaceutical, Regulatory/Compliance, Software / IT Tagged With: Abbott, Dexcom, embecta, Insulet, Mannkind Corp., Medtronic, Senseonics, Sequel Med Tech, Tandem Diabetes Care

MannKind inks $61m direct offering of common stock

October 11, 2017 By Sarah Faulkner

MannKind (NSDQ:MNKD) said today that it inked a deal with a group of unnamed investors for a registered direct offering of 10,166,600 shares of the company’s common stock for $6.00 apiece. The $61 million offering is slated to close later this week. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Diabetes, Drug-Device Combinations, Funding Roundup, Pharmaceutical, Wall Street Beat Tagged With: Mannkind Corp.

MannKind posts mixed Q2

August 8, 2017 By Sarah Faulkner

Shares in MannKind Corp. (NSDQ:MNKD) fell slightly this morning after the biopharmaceutical company missed earnings expectations but beat sales estimates on Wall Street with its second quarter results. The Valencia, Calif.-based company posted a net loss of -$35.4 million on sales of $2.2 million for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of […]

Filed Under: Diabetes, Drug-Device Combinations, MassDevice Earnings Roundup, Pharmaceutical, Wall Street Beat Tagged With: Mannkind Corp.

MannKind combines inhaled insulin with One Drop’s digital diabetes tech

August 7, 2017 By Sarah Faulkner

MannKind Corp. (NSDQ:MNKD) and One Drop said today that the group launched its A-One trial evaluating MannKind’s inhaled insulin, Afrezza, for use with One Drop’s digital diabetes management platform. The companies reported that they are enrolling people with Type II diabetes and randomizing them in two treatment arms. One group of patients will use Afrezza with One Drop […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Health Information Technology, Pharmaceutical, Wall Street Beat Tagged With: Mannkind Corp., One Drop

Lumicell taps ex-Accuray COO Londy as CEO | Personnel Moves July 18, 2017

July 19, 2017 By Fink Densford

Lumicell said last week it tapped former Accuray (NSDQ:ARAY) chief operating officer Kelly Londy as its new chief exec, with founder W. Lee moving to take the role of prez & chief scientific officer. Prior to holding the COO position at Accuray, Londy has held leadership positions at GE Healthcare (NYSE:GE) and Royal Philips (NYSE:PHG), Lumicell said. “We are […]

Filed Under: Business/Financial News Tagged With: Accuray Inc., Aptus EndoSystems Inc., Asante Solutions, AtriCure Inc., AxoGen, C.R. Bard, Cerner Corp., Cutera Inc., Eos Imaging, GE Healthcare, Lumicell, Mannkind Corp., Personnel Moves, Philips, Ventus Medical Inc., VertiFlex Inc., Zecotec

MannKind inks deal to bring inhaled insulin to Brazil

June 1, 2017 By Sarah Faulkner

MannKind Corp. (NSDQ:MNKD) said today that inked a supply and distribution deal with Biomm for the commercialization of its inhaled insulin, Afrezza, in Brazil. According to the agreement, Biomm will prepare and file the necessary applications for regulatory approval. MannKind will be responsible for manufacturing and supplying Afrezza and Biomm is slated to promote and […]

Filed Under: Diabetes, Drug-Device Combinations, Pharmaceutical, Research & Development, Wall Street Beat Tagged With: Mannkind Corp.

MannKind shares dip after Q1 sales miss consensus

May 12, 2017 By Sarah Faulkner

Shares in MannKind Corp. (NSDQ:MNKD) fell this week after the biopharmaceutical company missed expectations on Wall Street with its 1st quarter results. The Valencia, Calif.-based company pared its losses to -$16.3 million on sales of $3 million for the 3 months ended March 31, for bottom-line growth of 53% compared with the same period last year. […]

Filed Under: Drug-Device Combinations, MassDevice Earnings Roundup, Pharmaceutical, Wall Street Beat Tagged With: Mannkind Corp.

One Drop, MannKind ink partnership for connected, inhaled diabetes tech

May 5, 2017 By Sarah Faulkner

MannKind Corp. (NSDQ:MNKD) and One Drop said today that the companies agreed to ink a collaborative deal to add MannKind’s Afrezza inhaled insulin to One Drop’s digital diabetes management platform. The group plans to evaluate access and cost saving initiatives, customized patient coaching and innovative packaging for a reusable Afrezza inhaler integrated with Bluetooth tech. […]

Filed Under: Blog Tagged With: Mannkind Corp., One Drop

Mannkind taps medtech reps after Sanofi deal fails

June 28, 2016 By Varun Saxena

Mannkind chief commercial officer Michael Castagna is trying to resuscitate the inhaled insulin maker after its co-marketing agreement with Sanofi (NYSE:SNY) was cancelled at the beginning of the year due to disappointing sales. He’s fielding a team of about 70 people to sell the company’s Afrezza insulin inhaler, with about ⅓ coming from the medical […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations Tagged With: Mannkind Corp., Sanofi-Aventis

Ex-Insulet chief DeSisto out before he’s in at MannKind | Personnel Moves

January 11, 2016 By Fink Densford

  MannKind Corporation said today it withdrew an offer that would have made ex-Insulet (NSDQ:PODD) CEO Duane DeSisto its new CEO only 19 days after officially posting its offer to DeSisto. The offer was withdrawn as objections were raised by DeSisto’s former employer Insulet, who said the new position would violate its non-competition agreement, which will be […]

Filed Under: Business/Financial News Tagged With: Amazon, Australia Medtech Services, Bioventus LLC, BSN Medical, Cogentix Medical, Insulet, JenaValve, Mannkind Corp., Mauna Kea Technologies, oculartherapeutix, PathMaker Neurosystems Inc., Personnel Moves, Zoll Medical

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy